{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Weng JK"],"funding":["National Cancer Institute","NCI NIH HHS","Conquer Cancer Foundation","Cancer Prevention and Research Institute of Texas"],"pagination":["360-370"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9057640"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["111(2)"],"pubmed_abstract":["Purpose
There are limited prospective data on predictors of patient-reported outcomes (PROs) after whole-breast irradiation (WBI) plus a boost. We sought to characterize longitudinal PROs and cosmesis in a randomized trial comparing conventionally fractionated (CF) versus hypofractionated (HF) WBI.Methods and materials
From 2011 to 2014, women aged ≥40 years with Tis-T2 N0-N1a M0 breast cancer who underwent a lumpectomy with negative margins were randomized to CF-WBI (50 Gray [Gy]/25 fractions plus boost) versus HF-WBI (42.56 Gy/16 fractions plus boost). At baseline (pre-radiation), at 6 months, and yearly thereafter through 5 years, PROs included the Breast Cancer Treatment Outcome Scale (BCTOS), Functional Assessment of Cancer Therapy-Breast (FACT-B), and Body Image Scale"],"journal":["International journal of radiation oncology, biology, physics"],"pubmed_title":["Five-Year Longitudinal Analysis of Patient-Reported Outcomes and Cosmesis in a Randomized Trial of Conventionally Fractionated Versus Hypofractionated Whole-Breast Irradiation."],"pmcid":["PMC9057640"],"funding_grant_id":["R01 CA207216","P30 CA016672","R21 CA252411","R01 CA225646","R01 CA201487"],"pubmed_authors":["Tereffe W","Hortobagyi GN","Shaitelman SF","Strom EA","Hunt KK","Hoffman K","Schlembach P","Bloom ES","Arzu IY","Weng JK","Woodward WA","Buchholz TA","Grade E","Lei X","Perkins G","Reed VK","Chronowski G","Smith BD","Shah SJ","Dvorak T","Stauder MC"],"additional_accession":[]},"is_claimable":false,"name":"Five-Year Longitudinal Analysis of Patient-Reported Outcomes and Cosmesis in a Randomized Trial of Conventionally Fractionated Versus Hypofractionated Whole-Breast Irradiation.","description":"Purpose
There are limited prospective data on predictors of patient-reported outcomes (PROs) after whole-breast irradiation (WBI) plus a boost. We sought to characterize longitudinal PROs and cosmesis in a randomized trial comparing conventionally fractionated (CF) versus hypofractionated (HF) WBI.Methods and materials
From 2011 to 2014, women aged ≥40 years with Tis-T2 N0-N1a M0 breast cancer who underwent a lumpectomy with negative margins were randomized to CF-WBI (50 Gray [Gy]/25 fractions plus boost) versus HF-WBI (42.56 Gy/16 fractions plus boost). At baseline (pre-radiation), at 6 months, and yearly thereafter through 5 years, PROs included the Breast Cancer Treatment Outcome Scale (BCTOS), Functional Assessment of Cancer Therapy-Breast (FACT-B), and Body Image Scale","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Oct","modification":"2026-06-01T02:24:35.689Z","creation":"2026-04-08T09:15:23.37Z"},"accession":"S-EPMC9057640","cross_references":{"pubmed":["33992718"],"doi":["10.1016/j.ijrobp.2021.05.004"]}}